research use only

Bleximenib oxalate MLL inhibitor

Cat.No.E4679

Bleximenib oxalate(Menin-MLL inhibitor 24 oxalate) is an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL) . It can be used for the research of cancer.
Jump to

Quality Control

Batch: Purity: 99.40%
99.40

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (144.96 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : 100 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 689.83 Formula

C32H50FN7O3.C2H2O4

Storage (From the date of receipt)
CAS No. 2866179-95-3 Download SDF Storage of Stock Solutions

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC50/Ki
Menin-MLL
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-03)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03013998 RECRUITING
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Beat AML, LLC
2016-11 PHASE2; PHASE3
NCT07223814 RECRUITING
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland
2026-03-01 PHASE3
NCT06852222 RECRUITING
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
2025-06-04 PHASE3
NCT04811560 RECRUITING
Acute Leukemia
Janssen Research & Development, LLC
2021-05-19 PHASE1; PHASE2
NCT05453903 ACTIVE_NOT_RECRUITING
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
2022-10-04 PHASE1
NCT07295951 RECRUITING
Acute Lymphoblastic Leukemia; Acute Leukemias; Acute Myeloid Leukemia
Janssen Research & Development, LLC
2025-11-18 PHASE1

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.